Table 1.

Characteristics of invasive mucinous LDACs with novel gene fusions

No.SampleSexAgeSmoking (pack/year)Gene fusionChromosome aberrationOncogene mutationaPathologic stageTTF1HNF4A
1301TM55Ever (47)CD74-NRG1t(5;8)(q32;p12)None1a+
2AD12-108TF68NeverCD74-NRG1None2b+
3AD09-404TF78NeverCD74-NRG1None1a+
4AD13-199TF47NeverCD74-NRG1None1b+
5AD13-223TF53NeverCD74-NRG1None1a+
6AD13-379TF66NeverSLC3A2-NRG1t(8;11)(p12;q13)None1bNot testedNot tested
7436TM61Ever (41)EZR-ERBB4t(2;6)(q25;q34)None1b+
8AD08_127TF66NeverTRIM24-BRAFinv7(q33;q34)None1a++
9AD12-119TM62Current (63)KIAA1468-RETt(10;18)(q21;q11)None1a+
  • aEGFR, KRAS, BRAF, and HER2 mutations and ALK, RET, and ROS1 fusions.